Sodium Pyruvate
Tier C — Watch / tradeSodium Pyruvate
Targets：Reactive oxygen species
Indications (approved)：Idiopathic pulmonary fibrosis, 新冠后遗症, COVID-19, Chronic obstructive pulmonary disease, Prostate cancer, Asthma, Cystic fibrosis, 脑癌
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| Sodium Pyruvate-001 | 43165-43-1 | sodium 2,2-dihydroxypropanoate |
| Sodium Pyruvate | 113-24-6 | - |
Frequently asked questions
What are the approved indications of Sodium Pyruvate?
Approved indications include: Idiopathic pulmonary fibrosis, 新冠后遗症, COVID-19, Chronic obstructive pulmonary disease, Prostate cancer, Asthma, Cystic fibrosis, 脑癌.
When does the Sodium Pyruvate patent expire?
No public expiry year is available for Sodium Pyruvate yet; this page updates once verified.
How many synthesis routes are recorded for Sodium Pyruvate?
1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Sodium Pyruvate intermediates?
All intermediates in Sodium Pyruvate routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Sodium Pyruvate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22